uploads///Graph

Mavyret Is a Leading Drug in AbbVie’s HCV Franchise

By

Dec. 12 2018, Updated 7:30 a.m. ET

HCV revenue trends

AbbVie (ABBV) reported global HCV (hepatitis C) franchise sales worth $862 million in the third quarter, a YoY (year-over-year) rise of more than 100% on both an operational and a reported basis.

The company reported HCV sales of $444 million in the US market, a YoY rise of more than 100%. AbbVie also reported HCV sales of $418 million in international markets in the third quarter, YoY rises of 94.5% on a reported basis and 95.6% on an operational basis.

Article continues below advertisement

AbbVie reported global HCV sales worth $2.75 billion in the first nine months of 2018, a YoY rise of more than 100% on both an operational and a reported basis. The company reported HCV sales of $1.21 billion in the US market, a YoY rise of more than 100%. AbbVie also reported HCV sales of $1.54 billion in international markets in the third quarter, a YoY rise of more than 100% on both an operational and a reported basis.

As per the company’s third-quarter earnings conference call, it expects its HCV sales to be more than $3.5 billion in 2018.

The above diagram highlights the major clinical aspects of AbbVie’s leading HCV drug, Mavyret, which it launched commercially in the second half of 2017.

Mavyret revenue growth trends

In the third quarter, AbbVie reported Mavyret sales worth $839 million globally, a YoY rise of more than 100% on both an operational and a reported basis. Of this revenue, $444 million came from the US market, reflecting a YoY rise of more than 100% on both an operational and a reported basis.

The remaining $395 million came from international markets, reflecting a YoY rise of more than 100% on both an operational and a reported basis. As per the company’s third-quarter earnings conference call, Mavyret accounts for 50% of the global HCV market share.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.